Sigilon Therapeutics Financials

Sigilon Therapeutics Stock Summary

Sigilon Therapeutics competes with Reviva Pharmaceuticals, ZyVersa Therapeutics, Unicycive Therapeutics, Apollomics, and Cardio Diagnostics. Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Sigilon Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 66 people.

Sigilon Therapeutics Key Financial Ratios

Sigilon Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Sigilon Therapeutics's current stock value. Our valuation model uses many indicators to compare Sigilon Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sigilon Therapeutics competition to find correlations between indicators driving Sigilon Therapeutics's intrinsic value. More Info.Sigilon Therapeutics is rated third in return on equity category among its peers. It is rated fourth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sigilon Therapeutics' earnings, one of the primary drivers of an investment's value.

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

If you are still planning to invest in Sigilon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sigilon Therapeutics' history and understand the potential risks before investing.